Autoimmune Diseases  >>  opicinumab (BIIB033)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
opicinumab (BIIB033) / Biogen
NCT01244139: Safety Study of BIIB033 in Subjects With Multiple Sclerosis

Checkmark ACTRIMS-ECTRIMS 2014: MS
Sep 2014 - Sep 2014: ACTRIMS-ECTRIMS 2014: MS
Checkmark ECTRIMS 2013: Multiple sclerosis
Sep 2013 - Sep 2013: ECTRIMS 2013: Multiple sclerosis
Checkmark Data (MS)
More
Completed
1
47
US
BIIB033, Placebo
Biogen
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
04/12
04/12
NCT02641041: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

Completed
1
24
Europe
BIIB033, Placebo
Biogen
Central Nervous System (CNS) Demyelinating Disease, Multiple Sclerosis
09/16
09/16
NCT02833142: Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

Completed
1
28
US
BIIB033 (opicinumab)
Biogen
Multiple Sclerosis, Acute Optic Neuritis
11/16
11/16

Download Options